Deborah Waterhouse, ViiV Healthcare CEO (Hollie Adams/Bloomberg via Getty Images)
October 1, 2024 04:12 PM EDT
R&D
Pharma

GSK’s Vi­iV stops de­vel­op­ment of Phase 2 HIV an­tivi­ral

Kyle LaHucik

Senior Reporter

GSK’s Vi­iV Health­care has sus­pend­ed de­vel­op­ment of a Phase 2-stage HIV an­tivi­ral named VH3739937, a GSK spokesper­son con­firmed to End­points News on Tues­day.

The halt …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times